Announcement PDF Click to edit Master title style ENLITIC Investor Presentation 7 November 2024 © 2024 Enlitic, Inc. All rights reserved Important Notice and Disclaimer This presentation has been prepared by Enlitic, Inc. (Enlitic or the Company) to provide summary information about the Company and its associated entities as at the date of this presentation, and the information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation. The presentation is for informational purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or the law of any other jurisdiction. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision. No representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (each a Limited Party) guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation or the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation, including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. None of the Company or any of the other Limited Parties act, or are responsible, as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, securityholders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you. This presentation may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company’s beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “goals”, “aims”, “target” and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company’s control. As such, there can be no assurance that actual outcomes will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material. Any forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. As such, no undue reliance should be placed on any forward-looking statement, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the aftereffects of COVID-19 pandemic and certain geopolitical tensions. Past performance is not necessarily a guide to future performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. Nothing contained in this presentation, or any other information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company or any other Limited Party makes any representation or warranty as to the accuracy of any forward-looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation, and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forwardlooking statements in this presentation. Financial information contained in this presentation (if any) is unaudited, unless otherwise stated, and is therefore subject to change. You should be aware that this presentation has been prepared at a time when the review of the financial information contained in the presentation has not been completed and, accordingly, the Company takes no responsibility for, and can provide no assurance as to the reliability of, any information relating to the financial condition and/or financial and operating performance of the Company. Recipients of this presentation are cautioned therefore to not place any reliance on the financial (or other) information included in the presentation. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A$) unless otherwise stated. Certain market and industry data (including industry forecasts, projections, market sizes, market shares and market positions) included in this presentation has been obtained from public filings, research, surveys or studies conducted by third parties, including industry and general publications, which has not been independently verified by the Company, as well as from the Company’s own internal estimates and research. The Company cannot warrant or guarantee the adequacy, fairness, accuracy or completeness of such information. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. There is no assurance that any of the industry or market forecasts, including management estimates, which are referred to in this presentation will be achieved. In addition, such data involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. In addition, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source. This presentation may contain trademarks and trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with the Company. © 2024 Enlitic, Inc. All rights reserved AGENDA 1. Enlitic Overview 2. Laitek Acquisition 3. Enlitic Business Momentum 4. Key Industry Event 3 © 2024 Enlitic, Inc. All rights reserved Enlitic Overview 4 © 2024 Enlitic, Inc. All rights reserved WHAT WE DO The delivery of Ensight 2.0 lays the foundations for expanding capabilities ENLITIC CORE COMPETENCY Illustrative Example STUDIES DATA Tangible Benefit Use Case Description Hanging Protocols ENSIGHT 2.0 Proprietary AI Engine Improve Radiologist Productivity Puts time back in the hands of the radiologist AI orchestration Standardise Billing Accuracy Common Data Model Data Monetisation ENDEX Dictation template ENCOG ENCODE ENSIGHT ENSIGHT 2.0 USE CASES Operational Efficiencies H&S / Liability Mgmt 5 Contrast detection Identifies and prevents lost billing opportunities Anatomy detection Deidentification Data Curation Scan times Image orchestration Dose monitoring Laterality conflicts Delivers commercial insights and facilitates the potential sale of highly valuable curated data Drives revenue opportunities via increased patient throughput and reduced admin Tracks patient wellbeing / safety and reduces legal liability through correcting human errors © 2024 Enlitic, Inc. All rights reserved NECESSITY FOR ENLITIC USE CASES Ensight 2.0’s use cases have the potential to deliver significant value to our clients Improve Radiologist Productivity Improve and Enhance Data Quality Enlitic estimates that a medium sized health system can achieve an annual increase in revenues by up to c.$1.2M p.a.1 15% of extremity studies have unclear laterality, exposing radiology in the U.S. to a potential annual liability of c.$3.4B Inaccurate descriptions increase read times. Ensight 2.0 corrects study and series descriptions to decrease study read time by ~30 seconds2. Identify Billing Discrepancies Data Value Realisation Inaccurate laterality data increases risk and impacts care delivery. Ensight 2.0 reviews the data to identify potential laterality conflicts. Tempus AI generated c.$169M from the licensing of data and other analytical services in oncology in FY23 Non-standardised data reduces efficiency and poses significant challenges for research Realise Operational Efficiencies Ensight 2.0 standardises imaging data and increases data value. Missing or erroneous intravenous contrast could be underbilled in the U.S. by c.$2B p.a. A 5-minute reduction in average MRI scan times is expected to yield $250K per machine p.a. Incomplete and inaccurate data is one of the main causes of underbilling. Due to siloed, non-standardised data, healthcare organisations struggle to achieve cost savings. Ensight 2.0 reviews the imaging data to identify key procedure data discrepancies. Ensight 2.0’s ability to standardise data helps them achieve it. Healthcare generates 30% of the world’s data and almost 90% of that healthcare data is Medical Imaging Data (1) (2) Management estimates Management estimates derived from real life client examples. 6 © 2024 Enlitic, Inc. All rights reserved BALANCE SHEET STRENGTH Successful capital raise partially fund acquisition of Laitek and provide a robust Balance Sheet PLACEMENT • A$22,500,000 raised • Issue price: A$0.05 per security • A$100,000 contributed by Directors • All resolutions approved at general meeting OUTCOMES SECURITY PURCHASE PLAN • Date of closure: 6 November 2024 • Expected commitments: approx A$800,000 • Issue price: A$0.05 per security • All resolutions approved at general meeting 7 • Provision of significant financial strength to the company • Partial funding of acquisition of Laitek • Remainder should be sufficient to fund ongoing operations through to cash flow breakeven © 2024 Enlitic, Inc. All rights reserved Laitek Acquisition 8 © 2024 Enlitic, Inc. All rights reserved LAITEK ACQUISITION A strong strategic fit for Enlitic 1 Increase commercialisation Increase penetration of our products with clients 2 Add complementary products Enhance our product offering with additive product segments 3 Add to or strengthen our technological advantage Continue by strengthening and advancing our leading technology 4 Create value for securityholders Generate attractive returns from acquisitions by extracting the benefits © 2024 Enlitic, Inc. All rights reserved ABOUT LAITEK Tech-enabled healthcare data migration Key Recent Clients Laitek offers contract-based data migration services to US customers on a re-occurring basis as well as ongoing software licensing. OEM Partnership Model 93% FY23 revenue attributable to data migrations 0.7x1 $6.8M Estimated FY24 billings-based revenue multiple FY23 Statutory Revenue Direct Customers ~$1.0M Estimated annual cost savings from FY25+ 1 As at 2 September 2024 ~3.0yr Estimated Payback period (excl. revenue synergies) 10 © 2024 Enlitic, Inc. All rights reserved TECH ENABLED DATA MIGRATION An essential component of the medical imaging ecosystem TECH ENABLED DATA MIGRATION THE REALITY: HIGHLY COMPLEX THE PREMISE IS SIMPLE Many millions of studies encompassing petabytes of data are needed to be moved The process of extracting, translating and loading archived medical imaging data from one source (legacy PACS) to There is an extremely low margin of error and if performed incorrectly, may result in destruction of critical data another source (target PACS) Meticulous management of migration timings is necessary otherwise the entire PACS can crash, severely impacting patient wellbeing Reasons health systems typically undergo a migration Internal Upgrades Storage to cloud Cost Savings M&A Activity Extremely time consuming, often taking upwards of 12+ months to complete The migration software can take 10+ years and millions of dollars to develop 11 © 2024 Enlitic, Inc. All rights reserved STRATEGIC RATIONALE The Proposed Acquisition of Laitek is expected to deliver on Enlitic’s key objectives 1 Accelerates the value of our use cases 2 Moving critical technology in-house 3 4 • • • Combined service offering gives Enlitic immediate access to 10+ years of historical data while entrenching Ensight 2.0 Increased depth of data accelerates the value of our Use Cases for clients • Laitek’s routing capability is an essential technology for Enlitic which it would otherwise have to outsource at high cost Ability to tailor the capability to suit the implementation of Ensight 2.0 more efficiently Identification of highly convertible sales leads • • Established pipeline of migration contracts identifies Enlitic’s high value sales leads Strategically positioned for the structural industry evolution towards cloud-based storage Significant value creation for Enlitic's shareholders • • Compelling cost and commercial synergies evident given exceptionally comparable customer base Alignment exists in many aspects of the team structure and infrastructure 12 © 2024 Enlitic, Inc. All rights reserved ENLITIC & LAITEK Realising Value from Data DATA ACCESS Medical imaging data within & across sites is: • Locked Away, • Mixed Terminologies, • Unstructured, and • Proprietary Medical imaging, orders, data, and reports that are: • On Unstable Systems, • Complex, • Large Volume, and • Proprietary. This results in poor clinical, operational, financial, & research outcomes. Laitek’s AI-enabled platform and extensive expertise has the ability to unlock data. Solution Problem DATA ELEMENTS MIGRATE, MOVE, DE-ID, CONVERT Queens - ^ELB PCCS Area Proto Brain Ensure common terminology for optimal care: • Curation, • Enrichment, • Semantic Translation, and Standardization. Ensight’s unique CV & NLP AI gains a comprehensive understanding of data & automatically standardizes it. ACTIVATE Data access and refinement is foundational to driving: • Key Use Cases, • Data Analytics, • Data Intelligence, and • Data Literacy. Supports Clinical, Operational & Financial Excellence. ACHIEVE Data refinement ensures everyone, & every IT system uses the correct data for: • Insights, • New Revenue, • Higher ROI, and • Better Outcomes. Drive sustainable clinical, operational & financial goals. Enlitic, Laitek AI-Enabled Software Solutions IncidentalF CHR^Brian ASSURE STANDARDIZE DATA WORKFLOWS ROI CT Brain NONCON Increase Efficiency CR Upper Limb Simplify Display Protocols Configuration Identify Laterality Conflicts Reduce Risk (Body part, contrast use, etc., sent to billing) CT Brain NONCON Capture New Billing / RCM Info Maximize Billing CT Brain NONCON Accelerate Case Assignment Operational Excellence (Laterality conflicts identified in data) Discover, Interrogate, Index, CV / NLP © 2024 Enlitic, Inc. All rights reserved COMBINED BUSINESS PROGRESS Combined Offering Integrated Offering Sales Synergies Cost Reductions Development Support • Provide AI Enabled Workflow and Healthcare Data Migration Solutions • Enlitic plans to include Ensight 2.0 as part of data migration services, providing a differentiated and highly valued offering to drive market share growth • Integration of Enlitic and Laitek’s products into a fully comprehensive offering has started • Roadmap set to deliver AI Enabled Migrations to OEM partners in 2025 • Enlitic and Laitek sales functions have been combined and cross-functional selling has started • Sales team is actively selling the joint offerings • Right sizing of the combined businesses has begun and new organizational structure rolled out • On track with implementing cost savings synergies • Enlitic providing development and engineering to support Laitek and further improve the data migration tools • Laitek’s highly experienced implementation team to support Enlitic deployments 14 © 2024 Enlitic, Inc. All rights reserved Enlitic Business Momentum 15 © 2024 Enlitic, Inc. All rights reserved PIPELINE: ENSIGHT 2.0 We expect Ensight 2.0 to accelerate clients through the pipeline Note: The below logos constitute only a select portion of Enlitic’s current pipeline. There is no guarantee that these opportunities will progress to End User Licence Agreements or generate any revenue for Enlitic. OEM INTEGRATIONS PROOF OF CONCEPT (POC) / CONTRACTING1 POC SCOPING2 Ensight 2.0 ENHANCEMENTS WORKFLOWS CUSTOMIZATION (1) (2) POC / Contracting are parties actively in Proof of Concepts with Enlitic’s technology (i.e. deploying and testing it) or are engaged in discussions in respect of commercial contracting. POC scoping are clients in discussions to determine the POC testing frameworks and outcomes that the clients would like to see 16 © 2024 Enlitic, Inc. All rights reserved ENLITIC GROWTH Our expanded capabilities through Ensight 2.0 and Laitek have provided a springboard for growth Direct Clients Total Contract Value1 $8.0 20 US$M Direct Clients $7.5 $6.0 436% $4.0 $2.0 $- 15 30-Jun-23 1-Nov-24 In partnership with: 1 30-Jun-23 1-Nov-24 Channel Partners 10 $1.6 300% $1.0 $0.5 $0.4 30-Jun-23 Channel Partners $1.5 US$M In partnership with: 5 0 $2.0 (1) (2) 16 10 $1.4 Contracted ARR2 $- Recent New Contracts 8 6 4 2 0 1-Nov-24 In partnership with: 8 0 30-Jun-23 In partnership with: 1-Nov-24 TCV = Total Contracted Value. Represents the total contracted minimum license revenue to be charged over the term (generally 3 years of contracts entered into with customers) of the contract plus ancillary revenue (as applicable) ARR = Annual Recurring Revenue. The total annual revenue to be generated from current contracts that Enlitic has with its customer base NB: All values for remainder of presentation, unless otherwise stated, are in USD 17 © 2024 Enlitic, Inc. All rights reserved Key Industry Event 18 © 2024 Enlitic, Inc. All rights reserved INCREASING INDUSTRY PRESENCE Enlitic will have a strong presence at RSNA 2024, the world’s leading imaging conference 78% of attendees have purchasing power2 >41,000 people1 Radiological Society of North America Scientific Assembly & Annual Meeting 1-5 December 2024, Chicago, Illinois (1) (2) RSNA reported attendance at 2023 Meeting was more than 41,000 As reported by RSNA Showcasing the latest products and innovations Enlitic’s capabilities will be showcased in multiple locations throughout the exhibit hall, including:      RSNA’s Radiology Reimagined AI Showcase Enlitic Booth 4365 South Hall Laitek Booth 7707 North Hall Blackford Booth Panel discussion 10 Enlitic Partners to attend RSNA, with locations to showcase our solutions with our partners 19 © 2024 Enlitic, Inc. All rights reserved Thank you 20 © 2024 Enlitic, Inc. All rights reserved